The Effectiveness of 4% Niacinamide in A Case of Cutaneous Lupus
Abstract
Background: Niacinamide, also called nicotinamide, is the active form of niacin (nicotinic acid, vitamin B3). Niacinamide’s role in medicine continues to be studied due to its extensive effects and low toxicity. Various studies also suggest that niacinamide offers anti-inflammatory effects, improves the skin barrier, and acts as an anti-aging, brightening, and anticancer agent. Cutaneous lupus (CL) is a general term for a group of autoimmune connective tissue disorders affecting the skin that may be associated with systemic lupus erythematosus (SLE). There are plenty of treatment modalities for patients with CL, each with varying efficacy. Therapeutic options for CL can range from topical agents, including corticosteroids and calcineurin inhibitors, to systemic therapy, such as antimalarials, immunosuppressants, retinoids, thalidomide, and biological agents. Niacinamide is a topical agent widely used in various cases, one of which is CL. Objective: This case report aims to discuss the effectiveness of niacinamide as an adjuvant therapy in CL. Case Presentation: A 48-year-old woman with SLE and CL received systemic therapy consisting of methylprednisolone, hydroxychloroquine, and 4% niacinamide gel for 8 weeks. Results: Observations showed clinical improvement in CL lesions without any significant side effects. Conclusion: Therefore, 4% niacinamide gel therapy can be used as an adjuvant therapy.
Keywords
Full Text:
PDFReferences
Abbas, L. F., Nandy, K., & Chong, B. F. (2023). Classification of disease damage and activity in cutaneous lupus erythematosus: A cross-sectional analysis. Journal of the American Academy of Dermatology, 88(1). https://doi.org/10.1016/j.jaad.2022.04.045
Behera, B., Kumari, R., Gochhait, D., & Ayyanar, P. (2021). Dermoscopic appearance of an annular subacute cutaneous lupus erythematosus. In Dermatology Practical and Conceptual (Vol. 11, Issue 2). https://doi.org/10.5826/dpc.1102a13
Bitar, C., Menge, T. D., & Chan, M. P. (2022). Cutaneous manifestations of lupus erythematosus: a practical clinicopathological review for pathologists. In Histopathology (Vol. 80, Issue 1). https://doi.org/10.1111/his.14440
Boo, Y. C. (2021). Mechanistic basis and clinical evidence for the applications of nicotinamide (Niacinamide) to control skin aging and pigmentation. In Antioxidants (Vol. 10, Issue 8). https://doi.org/10.3390/antiox10081315
Chakka, S., Krain, R. L., Concha, J. S. S., Chong, B. F., Merola, J. F., & Werth, V. P. (2021). The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Annals of Translational Medicine, 9(5). https://doi.org/10.21037/atm-20-5048
Curtiss, P., Walker, A. M., & Chong, B. F. (2022). A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus. In Frontiers in Immunology (Vol. 13). https://doi.org/10.3389/fimmu.2022.866319
Damian, D. L. (2010). Photoprotective effects of nicotinamide. In Photochemical and Photobiological Sciences (Vol. 9, Issue 4). https://doi.org/10.1039/b9pp00146h
El Ters, M., Zhou, X., Lepping, R. J., Lu, P., Karcher, R. T., Mahnken, J. D., Brooks, W. M., Winklhofer, F. T., Li, X., & Yu, A. S. L. (2020). Biological Efficacy and Safety of Niacinamide in Patients With ADPKD. Kidney International Reports, 5(8). https://doi.org/10.1016/j.ekir.2020.06.002
Fijałkowska, A., Kądziela, M., & Żebrowska, A. (2024). The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review. In Journal of Clinical Medicine (Vol. 13, Issue 8). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/jcm13082419
Grönhagen, C., & Nyberg, F. (2014). Cutaneous lupus erythematosus: An update. Indian Dermatology Online Journal, 5(1), 7. https://doi.org/10.4103/2229-5178.126020
Gunawan, H., & Soeroso, J. (2018). The Coexistence of Systemic Lupus Erythematosus and Psoriasis: Is It Possible? The coexistence of SLE and psoriasis: Is it possible? In Acta Med Indones-Indones J Intern Med • (Vol. 50, Issue 2).
Hinduja, N., Mv, P., Padhee, S., Maikap, D., Padhan, P., Kar, H. K., Misra, R., Srinivas, C. R., & Ahmed, S. (2023). Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study. Rheumatology International, 43(10). https://doi.org/10.1007/s00296-023-05353-y
Jatwani S, & Hearth Holmes MP. (2023, July 31). Subacute Cutaneous Lupus Erythematosus. StatPearls.
Kang, Sewon., & Kang, S. (2019). Fitzpatrick’s dermatology. McGraw-Hill Education.
Kuhn, A., Aberer, E., Bata-Csörgő, Z., Caproni, M., Dreher, A., Frances, C., Gläser, R., Klötgen, H. W., Landmann, A., Marinovic, B., Nyberg, F., Olteanu, R., Ranki, A., Szepietowski, J. C., & Volc-Platzer, B. (2017). S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). In Journal of the European Academy of Dermatology and Venereology (Vol. 31, Issue 3). https://doi.org/10.1111/jdv.14053
Lu, Q., Long, H., Chow, S., Hidayat, S., Danarti, R., Listiawan, Y., Deng, D., Guo, Q., Fang, H., Tao, J., Zhao, M., Xiang, L., Che, N., Li, F., Zhao, H., Lau, C. S., Ip, F. C., Ho, K. M., Paliza, A. C., … Lin, C. S. (2021). Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. Journal of Autoimmunity, 123. https://doi.org/10.1016/j.jaut.2021.102707
Marques, C., Hadjab, F., Porcello, A., Lourenço, K., Scaletta, C., Abdel-Sayed, P., Hirt-Burri, N., Applegate, L. A., & Laurent, A. (2024). Mechanistic Insights into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products. Antioxidants, 13(4), 425. https://doi.org/10.3390/antiox13040425
McDaniel B, Sukumaran S, Koritala T, & et al. (2023, August 28). Discoid Lupus Erythematosus. StatPearls.
Mehta, A. B., Nadkarni, N. J., Patil, S. P., Godse, K. V., Gautam, M., & Agarwal, S. (2016). Topical corticosteroids in dermatology. In Indian Journal of Dermatology, Venereology and Leprology (Vol. 82, Issue 4). https://doi.org/10.4103/0378-6323.178903
Nouh, A. H., Elshahid, A. R., Kadah, A. S., & Zeyada, Y. A. (2023). Topical niacinamide (Nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study. Journal of Cosmetic Dermatology, 22(5). https://doi.org/10.1111/jocd.15628
Okon, L. G., & Werth, V. P. (2013). Cutaneous lupus erythematosus: Diagnosis and treatment. In Best Practice and Research: Clinical Rheumatology (Vol. 27, Issue 3). https://doi.org/10.1016/j.berh.2013.07.008
Szabó, Brodszky, V., & Rencz, F. (2022). A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16*. British Journal of Dermatology, 186(3). https://doi.org/10.1111/bjd.20765
Ürün, Y. G., Ürün, M., & Danişman, M. Ş. (2024). Dermoscopic Characteristics of Cutaneous Lupus Erythematosus According to Subtype, Lesion Location, Lesion Duration, and CLASI Score. Dermatology Practical and Conceptual, 14(1). https://doi.org/10.5826/dpc.1401a40
Vale, E. C. S. do, & Garcia, L. C. (2023). Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. In Anais Brasileiros de Dermatologia (Vol. 98, Issue 3). https://doi.org/10.1016/j.abd.2022.09.005
Verdelli, A., Corrà, A., Mariotti, E. B., Aimo, C., Ruffo di Calabria, V., Volpi, W., Quintarelli, L., & Caproni, M. (2022). An update on the management of refractory cutaneous lupus erythematosus. In Frontiers in Medicine (Vol. 9). https://doi.org/10.3389/fmed.2022.941003
DOI: http://dx.doi.org/10.30742/jikw.v13i2.3592
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Anggun Putri Yuniaswan, Belladikna Brillianty Sugiatno
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
